Clinical pharmaceutical information interactive control method and equipment

Abstract

The invention discloses a clinical pharmaceutical information interactive control method. The method comprises the steps that clinical pharmaceutical information provided by a pharmaceutist account is acquired, and a corresponding notification message is generated based on the clinical pharmaceutical information; a plurality of doctor accounts associated with the clinical pharmaceutical information are determined, and the notification message is pushed to the doctor accounts; response data correspondingly fed back by the doctor accounts responding to the notification message is acquired, and data mining is performed on the response data to form mining result information pushed to the pharmaceutist account; and mark information of the doctor accounts providing the response data is updated to quantitatively reflect participation contributions of the doctor accounts. Through the clinical pharmaceutical information interactive control method and equipment, fast popularization of the clinical pharmaceutical information is realized, resource cost is saved, doctors are promoted to better use medicine, medication problems can be discovered in time, a potential safety hazard occurring to a patient is avoided, and a huge social benefit can be generated.

Description

technical field [0001] The present invention relates to the field of computer interactive control, more specifically, to a method and equipment for interactive control of clinical pharmacy information. Background technique [0002] The period from R&D to marketing of a new drug is very long. After the marketing, it is necessary to continue the phase IV clinical trial to provide continuous reference data for all aspects of the new drug. The so-called phase IV clinical trial is an open trial after marketing, and usually does not require a control group , but does not rule out conducting small-sample randomized controlled trials on certain indications or certain test subjects as needed. The number of cases in phase IV clinical trials needs to be in accordance with SDA regulations, and the number of cases is required to be greater than 2,000. In addition, although the phase IV clinical trial is an open trial, the relevant case selection criteria, exclusion criteria, withdrawal ...

AI Technical Summary

Problems solved by technology

However, in the current practice, the promotion efficiency of new drugs is low, the cost of promotion is huge, the cycle of receiving case feedback data is long, and the case data is biased, which seriously affects the progress of the later development of new drugs.

Images